Pemigatinib
Last Updated: 09/19/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 272 publications
FGFR2 fusion as the key to targeted therapy - a case report with a diagnostic turning point.
Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
Published: August 28, 2026
Successful treatment using pemigatinib in a myeloid/lymphoid neoplasm with eosinophilia with FGFR1 rearrangement and rare chromosomal abnormalities.
Journal: Leukemia & lymphoma
Published: August 23, 2026
Pemigatinib in the Treatment of Metastatic, Inflammatory Triple-Negative Breast Cancer With FGFR2 Rearrangement: A Case Report and Review of the Literature.
Journal: JCO precision oncology
Published: August 12, 2026
From progression to complete remission - a case study of successful pemigatinib treatment in a patient with metastatic FGFR2+ cholangiocarcinoma.
Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
Published: June 22, 2026
FGFR2 Fusion Gene-Positive Solid Tumors
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: June 04, 2026
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 01, 2026
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 01, 2026
Real-world patient characteristics and utilization patterns in patients with cholangiocarcinoma who received pemigatinib in the United States of America.
Journal: ESMO real world data and digital oncology
Published: May 04, 2026
Calciphylaxis as a Rare Complication Associated with Pemigatinib Treatment-A Case Report.
Journal: Current oncology (Toronto, Ont.)
Published: March 18, 2026
Management of Nail Toxicities From Fibroblast Growth Factor Receptor Inhibitors.
Journal: Journal of drugs in dermatology : JDD
Published: March 04, 2026
Integrative multi-omics and single-cell analysis identifies EGFR pathway activation and metabolic reprogramming as potential synthetic lethal vulnerabilities in resistance to the FGFR inhibitor AZD4547.
Journal: Journal of translational medicine
Published: February 18, 2026
Last Updated: 09/19/2026